3.86
전일 마감가:
$3.86
열려 있는:
$3.74
하루 거래량:
143.60K
Relative Volume:
1.35
시가총액:
$32.49M
수익:
$140.46M
순이익/손실:
$-146.34M
주가수익비율:
-3.0394
EPS:
-1.27
순현금흐름:
$-117.73M
1주 성능:
-7.21%
1개월 성능:
-39.40%
6개월 성능:
-71.00%
1년 성능:
-80.65%
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
명칭
Karyopharm Therapeutics Inc
전화
617-658-0600
주소
85 WELLS AVENUE, NEWTON, MA
KPTI을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
KPTI
Karyopharm Therapeutics Inc
|
3.86 | 32.49M | 140.46M | -146.34M | -117.73M | -1.27 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2023-01-19 | 개시 | Piper Sandler | Overweight |
2022-11-04 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
2022-02-09 | 업그레이드 | JP Morgan | Underweight → Neutral |
2021-11-19 | 재개 | Morgan Stanley | Equal-Weight |
2021-08-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2021-08-06 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2021-08-06 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
2020-07-02 | 개시 | Morgan Stanley | Overweight |
2020-03-04 | 개시 | Barclays | Overweight |
2020-01-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
2019-07-23 | 업그레이드 | JP Morgan | Neutral → Overweight |
2019-07-05 | 재확인 | H.C. Wainwright | Buy |
2019-07-05 | 재확인 | Robert W. Baird | Outperform |
2019-03-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2019-02-28 | 재확인 | BofA/Merrill | Underperform |
2019-02-27 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
2019-01-03 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
2018-12-03 | 개시 | B. Riley FBR | Buy |
2018-11-09 | 업그레이드 | Wedbush | Neutral → Outperform |
2018-05-24 | 다운그레이드 | Wedbush | Outperform → Neutral |
2018-04-02 | 재개 | Leerink Partners | Outperform |
2017-11-15 | 재개 | H.C. Wainwright | Buy |
2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
2016-09-08 | 재확인 | H.C. Wainwright | Buy |
2016-08-30 | 업그레이드 | Jefferies | Hold → Buy |
2016-08-18 | 개시 | H.C. Wainwright | Buy |
2016-06-28 | 개시 | Robert W. Baird | Outperform |
모두보기
Karyopharm Therapeutics Inc 주식(KPTI)의 최신 뉴스
Karyopharm Therapeutics (NASDAQ:KPTI) Shares Pass Below Two Hundred Day Moving Average – Time to Sell? - Defense World
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Piper Sandler cuts Karyopharm stock target to $15 from $75 - Investing.com
Piper Sandler cuts Karyopharm stock target to $15 from $75 By Investing.com - Investing.com South Africa
Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below 200-Day Moving Average – Time to Sell? - Defense World
Karyopharm Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Karyopharm therapeutics SVP sells $17,567 in shares By Investing.com - Investing.com Canada
Karyopharm therapeutics CEO Richard Paulson sells $73,555 in stock By Investing.com - Investing.com South Africa
Karyopharm Therapeutics Executives Sell Shares - TradingView
Karyopharm therapeutics CEO Richard Paulson sells $73,555 in stock - Investing.com
Karyopharm therapeutics SVP sells $17,567 in shares - Investing.com India
Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Lowered to $54.00 at Robert W. Baird - Defense World
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Karyopharm Therapeutics Inc. To Contact The Firm - ACCESS Newswire
Karyopharm Therapeutics Inc. (KPTI), Mallinckrodt plc (MNK) & National General Holdings Corp. (NGHC)Bronstein, Gewirtz & Grossman, LLCClass Action Reminder - ACCESS Newswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MENAFN.COM
KPTI Stock Touches 52-Week Low at $7.58 Amid Market Challenges - Investing.com
Karyopharm Therapeutics (KPTI) Projected to Post Earnings on Thursday - MarketBeat
International Myeloma Foundation (IMF) Celebrates Myeloma Milestones for 2025 Myeloma Action Month - GlobeNewswire Inc.
Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Raised to $56.00 - Defense World
HC Wainwright Forecasts Strong Price Appreciation for Karyopharm Therapeutics (NASDAQ:KPTI) Stock - MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Down 93.1% in February - MarketBeat
Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Down 9%What's Next? - MarketBeat
Karyopharm Therapeutics (NASDAQ:KPTI) Sees Large Volume Increase After Analyst Upgrade - MarketBeat
HC Wainwright Issues Optimistic Estimate for KPTI Earnings - MarketBeat
FY2025 Earnings Estimate for KPTI Issued By Leerink Partnrs - MarketBeat
Karyopharm Therapeutics (KPTI) to Release Quarterly Earnings on Thursday - Defense World
Karyopharm Therapeutics Inc.’s SWOT analysis: biotech firm’s stock faces pivotal year - Investing.com India
Karyopharm Therapeutics Inc.’s SWOT analysis: biotech firm’s stock faces pivotal year By Investing.com - Investing.com South Africa
Research Analysts Issue Forecasts for KPTI Q1 Earnings - MarketBeat
Royal Bank of Canada Reaffirms Outperform Rating for Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat
Karyopharm announces 1-for-15 reverse stock split - MSN
Karyopharm enacts 1-for-15 reverse stock split to boost price - Investing.com Australia
Karyopharm enacts reverse stock split to meet Nasdaq standards By Investing.com - Investing.com South Africa
Karyopharm enacts reverse stock split to meet Nasdaq standards - Investing.com
Karyopharm Unveils 1-for-15 Reverse Stock Split, Effective February 25, 2025 - Nasdaq
Karyopharm Therapeutics to Implement 1-for-15 Reverse Stock Split -February 24, 2025 at 01:18 pm EST - Marketscreener.com
Karyopharm Announces 1-for-15 Reverse Stock Split - Citizentribune
Karyopharm enacts 1-for-15 reverse stock split to boost price By Investing.com - Investing.com South Africa
Leerink Partnrs Has Pessimistic View of KPTI FY2025 Earnings - Defense World
Research Analysts Offer Predictions for KPTI Q1 Earnings - Defense World
What is Leerink Partnrs’ Estimate for KPTI Q1 Earnings? - The AM Reporter
Karyopharm Therapeutics’ (KPTI) “Buy” Rating Reiterated at HC Wainwright - Defense World
Karyopharm’s 2024 Earnings and Clinical Progress - TipRanks
HC Wainwright Reaffirms "Buy" Rating for Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat
Karyopharm targets $1B revenue potential for Selinexor in myelofibrosis amid Phase 3 progress - MSN
H.C. Wainwright maintains Buy on Karyopharm with $7 target By Investing.com - Investing.com South Africa
Karyopharm’s Earnings Call: Growth Amid Financial Challenges - TipRanks
Karyopharm Therapeutics: Strong Financial Performance and Strategic Developments Justify Buy Rating - TipRanks
Karyopharm Therapeutics (NASDAQ:KPTI) Announces Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Karyopharm Therapeutics Inc (KPTI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):